G2G raises ‘peptide inclusion rate’ to 50%
Inventage Lab collaborates with Boehringer and Peptron collaborates with Lilly.
‘Microsphere technology’ is most suitable for obesity treatment, etc.
Big global pharma companies such as Novo Nordisk and Eli Lilly, which are creating a sensation with their obesity treatment products, are paying attention to the long-lasting technologies of domestic companies. Long-acting technology is a technology that maintains effects for a long time once the drug is administered. Domestic companies are securing global technological competitiveness by proactively developing microsphere technology suitable for long-lasting obesity treatment.
According to the industry on the 27th, domestic long-term technology companies are concluding collaborations with global big pharma companies one after another. G2G Bio plans to attend the Boston Conference (PODD), a long-lasting technology-related conference, on the 28th and reveal its 50% peptide injection technology. Lee Hee-yong, CEO of G2G Bio, said, “In the first generation, we used semaglutide to increase the encapsulation rate of injecting drugs into microspheres to 10%, and in the second generation, we added terzepatide to 20%.” He added, “In the third generation, we used peptide ingredients to reduce obesity. “We added up to 50% of the treatment drug,” he explained. G2GBIO achieved this through the ‘InnoLamp’ platform, which improved the problem of drug content and bioavailability loaded with microspheres. If the encapsulation rate is high, a large amount of drug can be loaded into the microspheres while reducing side effects and maintaining stable efficacy.
Inventage Lab (389470) has decided to jointly develop long-acting injections for new peptide drugs with Boehringer Ingelheim. Inventage Lab’s ‘IVL-DrugFluidic’ technology is a formulation platform that utilizes high-quality polymer microspheres to achieve long-lasting effects while minimizing the side effects of the drug. Through Boehringer Ingelheim’s internal evaluation process, we plan to jointly respond to clinical development, manufacture clinical samples, and enter into a global supply agreement for commercialization. An Inventage Lab official said, “Boehringer Ingelheim’s final commercialization of the joint development project is very likely.”
Peptron (087010) also signed a platform technology evaluation agreement to promote joint research on applying the ‘Smart Depot’ platform technology to Eli Lilly’s peptide drugs. Eli Lilly’s peptide preparation has a limitation in that it decomposes quickly before being absorbed into the body, reducing its effectiveness. Smart Depot is a technology that stores drugs in microspheres that decompose in the body and releases them slowly over a long period of time. Eli Lilly is likely to apply peptide drugs such as Retatrutide, which is considered a candidate for next-generation obesity treatment, to Smart Depot.
Novo Nordisk’s Wigobi is a glucagon-like peptide-1 (GLP-1) drug, and Maunzaro is a glucose-dependent insulinotropic polypeptide (GIP)·GLP-1 dual agonist. Among long-lasting technologies such as microspheres developed by Takeda, Amgen’s antibody-conjugated method, and Novo Nordisk’s albumin-conjugated method, the microsphere method is considered the technology that can maintain GLP-1 efficacy for the longest time. When peptides enter the body, they dissolve quickly and have a short medicinal effect, but if they are made into microspheres and injected, the drug can be released slowly. CEO Lee said, “Takeda has been developing microspheres only for the treatment of prostate cancer, and Alkermis in the U.S. has received many approvals from the U.S. Food and Drug Administration (FDA), but has not been focusing on technology development recently.” He added, “Domestic companies are proactively developing microspheres. “As we have developed and advanced technology, we are evaluated as having global competitiveness,” he said.
